Sponsors (7)
Introduced December 3, 2025 by Pete Sessions · Last progress December 3, 2025
The bill creates a government-backed investment vehicle to channel new and sustained capital into U.S. critical and emerging technologies (notably biotech) with professional management and faster implementation, but it increases taxpayer financial exposure, reduces procedural safeguards and oversight, and creates compliance and foreign-capital trade-offs for affected firms.
Startups and small U.S. technology firms (especially seed-to-mid-stage companies) gain new direct financing (typical $1M–$10M) plus a $300M FY2025 biotechnology allocation, improving access to capital for growth and commercialization.
Biotech researchers and companies receive targeted, sustained support (policy priority, dedicated FY2025 funding, and a conditional backstop), strengthening public-health-relevant and other ‘critical and emerging’ technology development.
Taxpayers and investors benefit from a governance structure intended to improve investment quality and accountability — independent professional management, private-sector advisory boards, and required performance reporting aim to produce better returns and oversight of public investments.
Taxpayers face substantial new spending and financial exposure — roughly $975.5M up front (plus potential later supplemental authority up to $500M) and the risk that Fund losses or underperformance ultimately impose costs on the public.
Individuals and businesses lose procedural protections and public oversight: exemptions from APA notice-and-comment and PRA clearance reduce opportunities for public input and OMB oversight, increase risk of arbitrary decisions, and weaken congressional and public accountability.
Companies and researchers may face shifting eligibility, higher compliance costs, and competitive risks because key definitions are tied to an externally updatable NSTC list, broad agency-linked definitions (e.g., 'foreign entity of concern'), and mandated reporting that could disclose sensitive project information.
Based on analysis of 8 sections of legislative text.
Creates a Treasury-run fund to invest federal capital in critical and emerging technologies (biotech priority), sets governance and reporting rules, and authorizes specified appropriations.
Creates a new Independence Investment Fund inside the Treasury to make equity investments in U.S. critical and emerging technologies that advance national and economic security, with biotechnology named as a priority. The Fund will be run by an independent managing entity selected through competition, overseen by a Treasury-led advisory board, report annually to Congress, be exempt from certain administrative and paperwork laws, and is backed by specified appropriations totaling about $975.5 million for FY2025 plus multi-year operating funding and conditional supplemental authorizations through FY2040.